Lipocalin-2, A-FABP and inflammatory markers in relation to flow-mediated vasodilatation in patients with essential hypertension

Clinical and Experimental Hypertension

Volumn 36, Issue 7, 2014, Pages 478-483

  Park, Chang G ^a   Choi, Kyung M ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Adipocyte fatty acid binding protein; Adipokine; Hypertension; Lipocalin 2; Metabolic syndrome

Indexed keywords

C REACTIVE PROTEIN; CREATININE; FATTY ACID BINDING PROTEIN 4; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 10; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; TRIACYLGLYCEROL; ACUTE PHASE PROTEIN; AUTACOID; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; GLUCOSE BLOOD LEVEL; IL10 PROTEIN, HUMAN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PATHOGENESIS; PATHOPHYSIOLOGY; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION; WAIST CIRCUMFERENCE; BLOOD; BLOOD PRESSURE; CASE CONTROL STUDY; HYPERTENSION; METABOLIC SYNDROME X; METABOLISM; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTOR;

ACUTE-PHASE PROTEINS; ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-10; LIPOCALINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; REGRESSION ANALYSIS; RISK FACTORS; VASODILATION;

EID: 84911908157     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2013.863320     Document Type: Article

References (29)

1. Matsuzawa Y. Therapy insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006;3:35-42.
2. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.
3. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMPactivated protein kinase. Nat Med 2002;8:1288-95.
4. Adamczak M, Wiecek A, Funahashi T, et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003;16:72-5.
5. Wang Y, Lam KS, Kraegen EW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007;53: 34-41.
6. Kratchmarova I, Kalume DE, Blagoev B, et al. A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes. Mol Cell Proteom 2002;1:213-22.
7. Meheus LA, Fransen LM, Raymackers JG, et al. Identification by microsequencing of lipopolysaccharide-induced proteins secreted by mouse macrophages. J Immunol 1993;151:1535-47.
8. Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006;52:405-13.
9. Xu A, Tso AW, Cheung BM, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007;115: 1537-43.
10. Yeung DC, Xu A, Cheung CW, et al. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007;27: 1796-802.
11. Das UN. Metabolic syndrome X: an inflammatory condition? Curr Hypertens Rep 2004;6:66-73.
12. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
13. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA 2003;290:2945-51.
14. Nicoletti F, Mancuso G, Ciliberti FA, et al. Endotoxin-induced lethality in neonatal mice is counteracted by interleukin-10 (IL-10) and exacerbated by anti-IL-10. Clin Diagn Lab Immunol 1997;4: 607-10.
15. Esposito K, Pontillo A, Giugliano F, et al. Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab 2003;88:1055-8.
16. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
17. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19.
18. Borregaard N, Cowland JB. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals 2006;19:211-15.
19. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-62.
20. Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-63.
21. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004;432:917-21.
22. Devireddy LR, Teodoro JG, Richard FA, Green MR. Induction of apoptosis by a secreted lipocalin that is transcriptionally regulated by IL-3 deprivation. Science 2001;293:829-34.
23. Hemdahl AL, Gabrielsen A, Zhu C, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006;26:136-42.
24. Makowski L, Hotamisligil GS. Fatty acid binding proteins-the evolutionary crossroads of inflammatory and metabolic responses. J Nutr 2004;134:2464S-8S.
25. Maeda K, Cao H, Kono K, et al. Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 2005;1:107-19.
26. Makowski L, Brittingham KC, Reynolds JM, et al. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome proliferator-activated receptor gamma and IkappaB kinase activities. J Biol Chem 2005;280: 12888-95.
27. Boord JB, Maeda K, Makowski L, et al. Adipocyte fatty acidbinding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002; 22:1686-91.
28. Tuncman G, Erbay E, Hom X, et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci USA 2006;103:6970-5.
29. Ota H, Furuhashi M, Ishimura S, et al. Elevation of fatty acidbinding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens 2012; 25:1124-30.